Welcome to our dedicated page for Cytomx Therapeutics news (Ticker: CTMX), a resource for investors and traders seeking the latest updates and insights on Cytomx Therapeutics stock.
CytomX Therapeutics develops oncology biologics built on its PROBODY therapeutic platform, which masks and conditionally activates antibody-based therapies in the tumor microenvironment. News about CTMX commonly covers clinical updates for varsetatug masetecan, or Varseta-M, an EpCAM PROBODY ADC studied in advanced colorectal cancer and other EpCAM-expressing tumors, as well as CX-801, a masked Interferon-alpha-2b program initially developed in advanced melanoma.
Company updates also address financial results, research and development spending, cash runway, equity financings, and collaboration activity with Amgen, Regeneron, and Moderna. Recurring pipeline coverage includes dose-expansion data, combination-study activity, regulatory interactions, and PROBODY platform applications such as bispecific immunotherapies and T-cell engagers.
CytomX Therapeutics (Nasdaq: CTMX) will report its second quarter 2026 financial results on Thursday, August 6, 2026, after the close of U.S. markets. The company will host a conference call and webcast at 5:00 p.m. ET / 2:00 p.m. PT, accessible via the Events and Presentations page of its investor relations website, with advance registration recommended.
CytomX is a clinical-stage, oncology-focused biopharmaceutical company developing masked, conditionally activated PROBODY therapeutics. Its clinical pipeline includes varsetatug masetecan (Varseta-M; CX-2051), a masked ADC targeting EpCAM for metastatic colorectal cancer, and CX-801, a masked interferon alpha-2b PROBODY cytokine initially for metastatic melanoma. The company also maintains strategic collaborations with Amgen, Regeneron and Moderna.
CytomX Therapeutics (Nasdaq: CTMX) has appointed Charles Fuchs, M.D., M.P.H., a board-certified medical oncologist with over three decades of oncology leadership, to its Board of Directors. Fuchs most recently served as Chief Medical Officer of Tubulis and previously led global oncology and hematology drug development at Genentech and Roche, where he oversaw approvals for therapies including Lunsumio, Columvi, Polivy and Tecentriq.
According to CytomX, his expertise in gastrointestinal oncology is expected to support advancement of varsetatug masetecan (Varseta-M; CX-2051), an EpCAM-directed antibody-drug conjugate for metastatic colorectal cancer, and CX-801, a masked interferon alpha-2b PROBODY cytokine initially in development for metastatic melanoma.
CytomX (NASDAQ: CTMX) expanded its strategic research and licensing collaboration with Regeneron to develop conditionally activated bispecific cancer therapies using PROBODY and Veloci-Bi platforms.
CytomX will receive a $37 million target nomination payment, with total potential milestones of up to approximately $4 billion and tiered royalties, while Regeneron funds preclinical, clinical and commercialization activities.
CytomX Therapeutics (Nasdaq: CTMX) announced management participation in two June 2026 investor conferences. Events include fireside chats and one-on-one investor meetings.
Jefferies Global Healthcare Conference: June 4, 2026, 3:10 p.m. ET, New York, NY. Goldman Sachs 47th Annual Global Healthcare Conference: June 10, 2026, 9:20 a.m. ET, Miami, FL. Live webcasts will be available on CytomX’s website.
CytomX Therapeutics (Nasdaq: CTMX) appointed Mamata Gokhale, Ph.D., RAC as Senior Vice President of Regulatory Affairs, effective May 18, 2026. She will lead global regulatory strategy and interactions to advance CytomX’s PROBODY pipeline, including lead program Varseta-M, toward clinical development milestones and potential commercialization.
CytomX Therapeutics (Nasdaq: CTMX) reported Q1 2026 results and a business update on May 7, 2026. Cash, cash equivalents and investments were $346.7 million with runway to at least H2 2028 after a $250 million March follow-on offering. Total revenue was $10.3 million versus $50.9 million in Q1 2025. Varsetatug masetecan (Varseta-M) completed enrollment of 40 patients in dose optimization (8.6 and 10 mg/kg Q3W); additional data expected in H2 2026 to inform monotherapy dose and potential registrational trial targeting 1H 2027. Multiple combination and expansion studies are planned through 2027. CX-801 development and collaborations with Amgen, Regeneron, and Moderna continue.
CytomX Therapeutics (Nasdaq: CTMX) will report first quarter 2026 financial results on Thursday, May 7, 2026 after U.S. market close. The company will host a conference call and live webcast at 5:00 p.m. ET / 2:00 p.m. PT, with an archived replay available on its investor website.
CytomX (Nasdaq:CTMX) priced an underwritten public offering to raise approximately $250.0 million in gross proceeds by selling 45,990,567 shares of common stock at $5.30 per share and pre-funded warrants for 1,179,245 shares.
The company granted a 30-day option for an additional 7,075,471 shares and expects to close on March 19, 2026. Net proceeds are expected to fund continued development of Varseta-M and other pipeline programs, with remaining proceeds for capital expenditures, working capital and general corporate purposes.
CytomX Therapeutics (NASDAQ:CTMX) has commenced an underwritten public offering of $250.0 million of common stock and, for certain investors, pre-funded warrants, with a 30-day underwriter option to purchase up to an additional $37.5 million. The offering is subject to market and other conditions and may not be completed.
According to the company, net proceeds are expected to fund continued development of Varseta-M and other pipeline programs, with any remaining proceeds for capital expenditures, working capital and general corporate purposes. A shelf registration filed March 16, 2026, became effective upon filing.
CytomX (Nasdaq: CTMX) reported 2025 results and a business update on March 16, 2026. Key items: positive Phase 1 Varseta-M data in advanced colorectal cancer, FDA alignment targeted mid‑2026 for a registrational trial, initiated Varseta-M/bevacizumab combination, and CX‑801 combination data expected by end of 2026.
Financials: $137.1M cash at year‑end with runway to Q2 2027, 2025 revenue $76.2M (down from $138.1M), and 2025 operating expense $98.6M.